Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Investor in connection with Swedish Orphan Biovitrum’s rights issue
Mandate

Vinge advises Investor in connection with Swedish Orphan Biovitrum’s rights issue

April 01, 2011

Vinge is advising Investor AB in connection with Swedish Orphan Biovitrum AB’s (SOBI) rights issue for a total of approximately SEK 600 million subject to pre-emption rights of the existing shareholders. SOBI is listed on NASDAQ OMX Stockholm. Investor AB and Bo Jesper Hansen (SOBI’s chairman) have undertaken to subscribe for their share of the rights issue and the issue has been underwritten by Carnegie and Handelsbanken. As a consequence thereof, Investor has obtained the requisite dispensation from the Swedish Securities Council.

Vinge’s team advising Investor consists of Olle Sandersson, Pontus Enquist and Jesper Schönbeck.

Related

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of their production facility in Uppsala to Ofichem. The Uppsala site specializes in small-scale, early-phase development work.
August 13, 2025

Vinge advises Isofol Medical AB (publ) in connection with its rights issue of units

Through the rights issue of units, consisting of shares and warrants, and the exercised over-allotment issue, Isofol will receive approximately SEK 84 million and may receive an additional maximum of approximately SEK 110 million upon exercise of all warrants at the highest subscription price.
August 01, 2025

Vinge advises Oncorena in connection with share issue

 Vinge advises Oncorena Holding AB in connection with a share issue of approximately SEK 133 million.
July 30, 2025